-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Tisagenlecleucel (Kymirah) is the first anti-CD19 chimeric antigen receptor T cell (CAR T) therapy approved for marketing
.
In the JULIET flight trial, Tisagenlecleucel achieved an optimal response rate of 52% in 93 evaluable patients with relapsed/refractory aggressive B-cell lymphoma, and a complete response rate of 40%
Tisagenlecleucel (Kymirah) is the first anti-CD19 chimeric antigen receptor T cell (CAR T) therapy Tisagenlecleucel (Kymirah) is the first anti-CD19 chimeric antigen receptor T cell (CAR T) )therapy
This article reports the long-term follow-up results of the clinical prognosis, activity, and safety of the entire adult cohort
.
This is a multi-center, open-label, single-arm Phase 2 trial conducted at 27 treatment sites in 10 countries, recruiting histologically confirmed relapsed/refractory large B-cell lymphomas over 18 years of age The patient was given a single intravenous infusion of Tisagenlecleucel (5 x 108 CAR T cells)
.
The primary endpoint is the overall response rate
Total remission
Total remissionFrom July 29, 2015 to November 2, 2017, a total of 167 patients were recruited
.
As of February 20, 2020, 115 patients had received Tisagenlecleucel infusion and were included in the full analysis set
The overall response rate was 53.
Some adverse events
Some adverse eventsThe most common grade 3-4 adverse events were anemia (39%), decreased neutrophil count (34%), decreased white blood cell count (32%), decreased platelet count (28%), and cytokine release syndrome (23%).
%), neutropenia (20%), febrile neutropenia (17%), hypophosphatemia (13%) and thrombocytopenia (12%)
.
The most common treatment-related serious adverse events were cytokine release syndrome (27%), febrile neutropenia (6%), fever (5%), pancytopenia (3%), and pneumonia ( 3%)
In summary, Tisagenlecleucel has shown long-lasting activity and controllable safety in adult patients with relapsed or refractory aggressive B-cell lymphoma
.
For patients with large B-cell lymphoma who are refractory to chemotherapy or immunotherapy or who relapse after second-line treatment, Tisagenlecleucel has advantages over traditional treatment methods in terms of risk and benefit
Tisagenlecleucel has shown long-lasting activity and controllable safety in adult patients with relapsed or refractory aggressive B-cell lymphoma .
Original source:
Stephen J Schuster, et al.
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study in this message